Table 2.
ID | 1st NAC | Number of cycles (total weeks) | Clinical response | 2nd NAC (if any) | Number of cycles (total weeks) | Clinical response | Final surgery (RCB) | Local/distant relapse | Time to relapse (months) |
---|---|---|---|---|---|---|---|---|---|
Progression to metastatic disease | |||||||||
1 | TP | Two cycles (8 weeks due to delays for concern of abscess) | Initial clinical improvement, but radiographic progression and pulmonary metastatic disease on CT chest | None | N/A | Yes | 0 | ||
2 | AC (dd) | Four cycles (10 weeks due to delays) | Partial radiographic response on breast MRI | TP | Three cycles (11 weeks due to delays) | No response on CT chest | N/A | Yes | 0 |
Clinical or radiographic progression on any NAC | |||||||||
3a | T+Hsp90 inhibitoi | 1.5 cycles (5 weeks) | No radiographic response on breast MRI | TP | Three cycles (10 weeks due to delays) | Clinical and radiographic progression on breast MRI | III | Yes | 1.5 |
4b | AC | Four cycles (12 weeks) | Partial radiographic response on CT chest | TP | Three cycles (9 weeks) | Clinical progression | III | Yes | 8 |
5c | AC | Two cycles (6 weeks) | Clinical progression | None | II | Unknown | |||
No response or unknown response | |||||||||
6b | TAC | Six cycles (18 weeks) | Unknown | None | Not available | Yes | 4 | ||
7 | AC (dd) | Four cycles (8 weeks) | Unknown | TP | Four cycles (8 weeks) | Unknown | Not available | Yes | 11 |
8 | AC +vincristine | Four cycles (8 weeks) | Partial response by breast MRI | TP | Four cycles (12 weeks) | Unknown | II | Yes | 14 |
9 | AC (dd) | Four cycles (9 weeks due to delays) | Unknown | T TP |
One cycle (3 weeks) One cycle (3 weeks) |
Unknown | II | None | - |
10a | TP4 | Four cycles (12 weeks) | Minimal radiographic improvement on breast ultrasound | None | II | Unknown | |||
11 | TP | Four cycles (12–13 weeks due to delays) | Partial radiographic response on breast ultrasound | AC (dd) | Four cycles (8 weeks) | Unknown | II | None | |
12e | T | One cycle (3 weeks) | Radiographic progression on breast MRI | AC (dd) | Four cycles (8 weeks) | No response on MRI | II | None | - |
TP | Four cycles (12 weeks) | Clinical and radiographic improvement on breast MRI | |||||||
Radiographic or clinical improvement | |||||||||
13 | TC | Four cycles (12 weeks) | Radiographic improvement on breast MRI | None | II | Yes | 10 | ||
14f | T + Herceptin | Four cycles (12 weeks) | Radiographic improvement | None | Not available | None | - | ||
15 | AC (dd) | Four cycles (8 weeks) | Clinical improvement | TP | Four cycles (8 weeks) | Clinical and radiographic improvement on PET-CT | Not available | Unknown | |
16 | AC (dd) | Four cycles (8 weeks) | Radiographic improvement on breast MRI | T (dd) | Four cycles (9 weeks due to delay) | Clinical improvement | I | None | - |
Complete pathological response | |||||||||
17e | AC (dd) | Four cycles (8 weeks) | Clinical and radiographic improvement on breast MRI | T (dd) | Four cycles (8 weeks) | Radiographic improvement on mammogram | 0 | None | - |
18 | TP | Four cycles (12 weeks) | Complete radiographic response on breast MRI | AC (dd) | Four cycles (8 weeks) | Complete response on breast MRI | 0 | None | - |
A anthracycline-based therapy, C cyclophosphamide-based therapy, T Taxane-based therapy, P Platinum-based therapy, dd dose-dense
Received adjuvant AC
Received adjuvant hormonal therapy
Received adjuvant TP
Clinical trial J0785-Carboplatin/nab-paclitaxel/vorinostat
Received adjuvant capecitabine
Tumor is HER-2 + and patient received 1 year adjuvant Herceptin